Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sonoma Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
FRA:O8Z'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.83 Med: -0.16 Max: -0.03
Current: -0.58
During the past 13 years, the highest Debt-to-EBITDA Ratio of Sonoma Pharmaceuticals was -0.03. The lowest was -0.83. And the median was -0.16.
FRA:O8Z's Debt-to-EBITDA is ranked worse than 100% of 675
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs FRA:O8Z: -0.58
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sonoma Pharmaceuticals Debt-to-EBITDA Related Terms
Sonoma Pharmaceuticals Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sonoma Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:O8Z vs GELS, APUS, BTAI: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonoma Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sonoma Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Sonoma Pharmaceuticals (FRA:O8Z) has a Debt-to-EBITDA of -22.89 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sonoma Pharmaceuticals. According to the industry distribution chart, Sonoma Pharmaceuticals ranks #999999 out of 675 companies in the Drug Manufacturers industry.
Is Sonoma Pharmaceuticals' Debt-to-EBITDA too high?
Sonoma Pharmaceuticals' current Debt-to-EBITDA is -22.89. Based on the distribution chart, Sonoma Pharmaceuticals ranks #999999 out of 675 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sonoma Pharmaceuticals has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Sonoma Pharmaceuticals' Debt-to-EBITDA compare to GELS and APUS?
According to the Drug Manufacturers industry distribution chart, Sonoma Pharmaceuticals ranks #999999 out of 675 companies for Debt-to-EBITDA. This places Sonoma Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 675 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sonoma Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonoma Pharmaceuticals's current Debt-to-EBITDA is -22.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonoma Pharmaceuticals stock overvalued right now?
Sonoma Pharmaceuticals (FRA:O8Z) has a current Debt-to-EBITDA of -22.89. The stock's GF Value™ is €3.17, compared to a current price of €2.72 — trading 14.2% below its estimated fair value. The current Debt-to-EBITDA is -22.89. Sonoma Pharmaceuticals' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sonoma Pharmaceuticals (FRA:O8Z), the current Debt-to-EBITDA is -22.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonoma Pharmaceuticals (FRA:O8Z) Overvalued in 2026?
Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued.
The current stock price of €2.72 is trading 14.2% below its estimated GF Value™ of €3.17.
Key valuation signals for FRA:O8Z:
Debt-to-EBITDA: -22.89
GF Value™: €3.17 vs. price of €2.72 (14.2% below fair value)
No single metric tells the full story. See the FRA:O8Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
44GF Score
Get the complete analysis for FRA:O8Z
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O8Z has been successfully added to your 
